Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Aggressive Non-Hodgkin's Lymphoma”

114 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 114 results

Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics 86
Testing effectiveness (Phase 2)Study completedNCT00081861
What this trial is testing

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 13
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Large-scale testing (Phase 3)Ended earlyNCT01232556
What this trial is testing

Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Who this might be right for
Lymphoma, Non-Hodgkin
Pfizer 338
Testing effectiveness (Phase 2)WithdrawnNCT03212807
What this trial is testing

Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

Who this might be right for
EBV Related Non-Hodgkin's LymphomaPrimary CNS LymphomaPrimary Testicular Lymphoma
Singapore General Hospital
Testing effectiveness (Phase 2)Study completedNCT00052442
What this trial is testing

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Spectrum Pharmaceuticals, Inc 72
Not applicableActive Not RecruitingNCT01787409
What this trial is testing

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Who this might be right for
Aggressive Non-Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell Lymphoma+12 more
Mayo Clinic 565
Testing effectiveness (Phase 2)Study completedNCT00303953
What this trial is testing

PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell Lymphoma
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Looking for participantsNCT04440436
What this trial is testing

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

Who this might be right for
NHL
Beijing Immunochina Medical Science & Technology Co., Ltd. 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT00413036
What this trial is testing

Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, Non-Hodgkin's
Celgene 217
Testing effectiveness (Phase 2)Looking for participantsNCT06534437
What this trial is testing

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Who this might be right for
Non-Hodgkin Lymphoma, B-cell
Ryvu Therapeutics SA 178
Early research (Phase 1)Study completedNCT03003546
What this trial is testing

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Who this might be right for
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic Lymphoma+3 more
Mayo Clinic 9
Testing effectiveness (Phase 2)Study completedNCT01851551
What this trial is testing

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Who this might be right for
Non-Hodgkin's LymphomaDiffuse Large B-cell LymphomaMantle Cell Lymphoma
Acrotech Biopharma Inc. 22
Testing effectiveness (Phase 2)Ended earlyNCT04161118
What this trial is testing

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
University of Cologne 3
Early research (Phase 1)Study completedNCT03061188
What this trial is testing

Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma

Who this might be right for
Advanced Solid NeoplasmAggressive Non-Hodgkin LymphomaRecurrent Solid Neoplasm+3 more
Northwestern University 15
Large-scale testing (Phase 3)Study completedNCT03575351
What this trial is testing

Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 184
Early research (Phase 1)Active Not RecruitingNCT05299164
What this trial is testing

GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Who this might be right for
Non Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 18
Testing effectiveness (Phase 2)Ended earlyNCT00290706
What this trial is testing

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Northwestern University 32
Testing effectiveness (Phase 2)Study completedNCT00521560
What this trial is testing

Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas

Who this might be right for
Primary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's Lymphoma
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH 28
Load More Results